GLP-1 vs. Wegovy: What's the Difference?

Is Wegovy the same thing as "a GLP-1," or just one brand of it?

GLP-1 is a category, not a product. It's short for glucagon-like peptide-1 receptor agonist — a class of drugs that all work by mimicking a gut hormone your body already makes, slowing digestion and turning down appetite signals in the brain. Wegovy is one specific, FDA-approved product inside that category, not a stand-in for the whole thing.

Wegovy's active ingredient is semaglutide, the same molecule Novo Nordisk sells under two other brand names: Ozempic, approved in 2017 for type 2 diabetes, and Rybelsus, an oral tablet also approved for diabetes. Wegovy itself got its own FDA approval in June 2021, specifically for chronic weight management rather than blood sugar control. So the honest answer is that Wegovy is a GLP-1 — one particular brand of one particular molecule, dosed and labeled for one particular use.

What other GLP-1 options exist besides Wegovy?

Within the same molecule, semaglutide, you have a few paths: Ozempic if a prescriber uses it off-label for weight, Rybelsus as a daily pill instead of a weekly injection, and compounded semaglutide through a telehealth pharmacy at a lower price than any of Novo Nordisk's own products. All four deliver the same active ingredient; what differs is dose, form, FDA labeling, and cost.

Outside semaglutide entirely, there's tirzepatide — sold as Mounjaro for diabetes and Zepbound for weight management. Tirzepatide activates the same GLP-1 receptor plus a second one, GIP, which is why it's sometimes called a "twincretin" rather than a pure GLP-1. It's grouped into the same conversation because it treats the same conditions the same general way, and it currently produces the largest average weight-loss numbers of any drug in this category. The mechanism and head-to-head trial data are covered in full in our semaglutide vs. tirzepatide comparison rather than repeated here.

• Ozempic — semaglutide injection, FDA-approved for type 2 diabetes, sometimes prescribed off-label for weight.
• Rybelsus — semaglutide in a daily tablet, FDA-approved for type 2 diabetes only.
• Compounded semaglutide — same molecule, 503A pharmacy, not FDA-approved as a finished product, cheapest access point.
• Mounjaro / Zepbound — tirzepatide, a dual GLP-1/GIP-receptor drug; Mounjaro for diabetes, Zepbound for weight management.
• Compounded tirzepatide — same dual-mechanism molecule, 503A pharmacy, the cheapest tirzepatide access point.

Does Wegovy work better or worse than other GLP-1 drugs?

Wegovy's core evidence comes from the STEP 1 trial, published in the New England Journal of Medicine, where adults with obesity lost an average of 14.9% of their body weight over 68 weeks at the standard 2.4 mg dose, against 2.4% on placebo. That's the number the drug's original approval rests on.

In March 2026, the FDA reportedly approved a higher-strength version, Wegovy HD at 7.2 mg, after a trial showing about 20.7% average weight loss (worth confirming directly, since this is a recent regulatory detail). That's worth a caveat either way: it's a step-up option for people who've already tolerated the 2.4 mg dose for at least four weeks, not a starting dose, and gastrointestinal side effects were more frequent at that strength. It narrows the gap with other drugs in this category, not closes it.

That's because tirzepatide still holds the only true head-to-head win either molecule has — a trial that randomized patients to semaglutide or tirzepatide under the same protocol found a meaningfully larger average result with tirzepatide. Rybelsus, meanwhile, produces a more modest weight effect than injectable Wegovy — it's dosed and labeled for glucose control, not obesity — and compounded semaglutide should perform comparably to Wegovy at an equivalent dose, since it's the same active ingredient, though consistency depends on the individual pharmacy.

Is Wegovy safer than other GLP-1 options, or about the same?

Within the semaglutide family — Wegovy, Ozempic, Rybelsus, compounded semaglutide — the safety profile is essentially shared, because it's the same molecule doing the same thing in the body. Nausea, vomiting, diarrhea, and constipation are the most common issues across all of them, heaviest in the first months after a dose increase, and all semaglutide products carry the same boxed warning around thyroid C-cell tumors seen in rodent studies, with a contraindication for anyone with a personal or family history of medullary thyroid cancer or MEN2. Tirzepatide-based drugs cause the same general family of gastrointestinal effects, sometimes skewing toward slightly different symptoms, but not toward a meaningfully different risk category.

The safety axis that actually differentiates these options isn't Wegovy versus the drug class — it's brand versus compounded. FDA-approved products like Wegovy, Ozempic, Rybelsus, and Zepbound go through manufacturing oversight and finished-product testing that a compounded version, prepared individually by a 503A pharmacy, does not. That doesn't make compounded semaglutide unsafe by default, but it does mean the pharmacy's own quality practices matter more than they would with a branded product.

Is brand Wegovy or a compounded/generic GLP-1 cheaper?

This is where the brand-versus-class question turns into real dollars, and the spread is wide — from about $25 a month with the right insurance down to well over a thousand at full retail. Here's what each real option actually costs.

Fridays — cheapest verified compounded semaglutide

Fridays bundles medication, clinician visits, dietitian access, and coaching into one price: $150 a month on a 12-month plan, $249 a month if you'd rather stay month-to-month. It's best for someone comfortable committing to a year in exchange for the lowest verified all-in rate for a full-service compounded program — the trade-off is that annual prepayments are largely non-refundable, which is worth reading closely before committing.

Mochi Health — now priced per dose, not flat

Mochi built its reputation on flat pricing that didn't rise with your dose. That changed in 2026: medication now runs $60 to $99 a month depending on your prescribed dose, on top of a $79 monthly membership, putting the all-in range at $139 to $178 a month for semaglutide (and higher for tirzepatide, which Mochi also offers). It's best for someone who wants the lower starter-dose price and doesn't mind the cost climbing as they titrate up — the opposite of the flat-rate pitch Mochi used to be known for.

NovoCare self-pay — actual FDA-approved Wegovy, without insurance

If you specifically want brand-name Wegovy rather than a compounded semaglutide, Novo Nordisk's own self-pay program is the best-value way to get it without insurance. The pill runs from $149 a month at the starting dose up to $299 at the top maintenance doses. The pen costs $199 a month for your first two fills as a new patient, then $349 ongoing, or $399 at the newer 7.2 mg HD strength. It's best for someone who wants the name-brand product and its manufacturing oversight specifically, and is willing to pay more than compounded rates for that.

LillyDirect Zepbound — the tirzepatide alternative

If the bigger average result from tirzepatide's dual mechanism is worth paying for, LillyDirect sells FDA-approved Zepbound directly at $299 a month for the 2.5 mg starting dose, up to $449 for maintenance doses — as long as you refill within 45 days of your last shipment. Miss that window and the price jumps to $499 or $699 depending on dose. It's best for someone prioritizing the strongest average trial result over cost, and organized enough to track the refill deadline.

Rybelsus — the pill, but not the cheap option

Rybelsus is worth naming because it's genuinely a different form factor — a swallowed tablet instead of an injection — but it's not a budget play. Without insurance, cash price runs $900 to $1,100 a month, because Novo Nordisk hasn't built a self-pay program for it the way it has for Wegovy. With qualifying commercial insurance, a savings card can bring it down to $25 a month, the same as the injectables, but that offer applies to its diabetes indication, not off-label weight use. It's best for someone needle-averse with insurance coverage for the diabetes indication, and a poor fit for anyone paying entirely out of pocket.

Insurance plus a savings card — the cheapest pathway that exists

If your commercial insurance covers Wegovy or Zepbound for obesity and you qualify for the manufacturer's savings card, both land around $25 a month — a fraction of every self-pay figure above. Getting there requires prior authorization tied to BMI and often a documented comorbidity, and the card only works with commercial insurance, not Medicare or Medicaid.

Retail with no program — the price everything else is discounting from

This is the number you land on if none of the paths above apply to you: no insurance coverage for the drug, a savings card you don't qualify for or that's lapsed, and a pharmacy fill with no manufacturer or coupon program applied. At a retail pharmacy that way, Wegovy runs somewhere around $1,350 a month — the highest price on this page by a wide margin, and one almost nobody should actually pay. If you're staring at this number, the realistic ways out are the same ones covered above: check whether you qualify for NovoCare's self-pay program even without insurance (it's still far below retail), ask your prescriber about the savings card's eligibility rules, or look seriously at compounded semaglutide through a platform like Fridays if brand-name Wegovy specifically isn't a requirement for you.

• Insurance + savings card ($25/mo): about $300/year — the floor.
• Mochi Health per-dose semaglutide ($139–$178/mo): about $1,668–$2,136/year.
• Fridays compounded semaglutide ($150–$249/mo): about $1,800–$2,988/year.
• NovoCare Wegovy pill ($149–$299/mo by dose): about $1,788–$3,588/year.
• NovoCare Wegovy pen ongoing ($349–$399/mo): about $4,188–$4,788/year.
• LillyDirect Zepbound, on-time refills ($299–$449/mo): about $3,588–$5,388/year; lapsed refills ($499–$699/mo): about $5,988–$8,388/year.
• Rybelsus self-pay ($900–$1,100/mo): about $10,800–$13,200/year — the most expensive option that isn't full retail.
• Wegovy retail, no program (~$1,350/mo): about $16,200/year — the ceiling, and the outcome only someone with no coverage and no program lands on.

Where can you get Wegovy vs. a cheaper GLP-1 alternative online?

Brand-name Wegovy comes through two channels: a retail pharmacy with a prescription (at whatever price your insurance or a coupon gets you to), or NovoCare's own pharmacy and self-pay program, which ships directly and applies the same self-pay pricing whether you're uninsured or simply denied coverage. Zepbound works the same way through LillyDirect for tirzepatide specifically.

Compounded semaglutide and tirzepatide run through telehealth platforms like Fridays and Mochi Health — an online intake, a clinician visit, and fulfillment through the platform's compounding pharmacy partner, with the medication mailed to you. Rybelsus, being an oral tablet with a standard NDC, is filled at any retail pharmacy like most prescriptions; there's no telehealth-specific channel required for it.

Is compounded semaglutide a legitimate substitute for brand Wegovy?

It can be, within a narrower legal lane than existed a couple of years ago. The FDA declared the semaglutide shortage resolved in February 2025, which ended the broad compounding allowance that let pharmacies produce it at scale during the shortage years. What remains is a 503A individual-patient pathway: a compounding pharmacy can still prepare semaglutide for a specific patient when a prescriber documents a clinical reason the FDA-approved product won't work for them.

A separate proposal, announced in April 2026, would exclude semaglutide and tirzepatide from the bulk-ingredient list that larger 503B outsourcing facilities use — public comment closed that June, and no final rule had been issued as this page was checked. Whatever happens with that rule, legitimacy in the meantime comes down to the individual pharmacy: look for PCAB accreditation, clear sourcing, and a provider willing to explain how they document medical necessity, rather than assuming the molecule itself settles the question. Our Fridays review walks through what that looks like at one specific provider.

So is Wegovy the right pick for you at 40+, or is another GLP-1 a better fit?

• You want the FDA-approved brand and can afford it: NovoCare's self-pay Wegovy program, or the savings card if your insurance covers it, gets you the actual product with manufacturer oversight behind it.
• Cost is the deciding factor: compounded semaglutide through Fridays or Mochi undercuts every brand-name pathway, with Fridays' annual plan currently the lowest verified all-in price.
• You want the strongest average result and the cost premium doesn't scare you: tirzepatide through LillyDirect's Zepbound showed a bigger average outcome than semaglutide in head-to-head data, at a real cost difference.
• You're needle-averse and have diabetes-indicated insurance coverage: Rybelsus is worth asking your prescriber about, though it's a poor fit if you'd be paying its cash price out of pocket.
• You're not sure the hormonal weight shift of perimenopause is what you're dealing with, or want to weigh this against HRT first: it's worth reading how GLP-1s and hormone therapy compare before committing to either.